Let me introduce myself. My name is Mark Sisson. I’m 63 years young. I live and work in Malibu, California. In a past life I was a professional marathoner and triathlete. Now my life goal is to help 100 million people get healthy. I started this blog in 2006 to empower people to take full responsibility for their own health and enjoyment of life by investigating, discussing, and critically rethinking everything we’ve assumed to be true about health and wellness...Tell Me More
Overburdened doctors sure do love tangible targets, like lipid numbers. They’re easy to hit with drugs. There’s no guesswork – statins and the like actually do lower cholesterol (whether that’s helpful or harmful is the question) – and that makes a physician’s life simpler. Oh, sure, lifestyle changes work, but most patients won’t bother trying them (especially when the changes you prescribe are founded in faulty science and no fun following). Doctors can usually get patients to take a pill.
There’s yet another cholesterol-busting wonder drug on the coming horizon called anacetrapib. A recent eighteen-month trial found that it boosted HDL (from 40 to 101) 138% greater than placebo and slashed LDL (from 81 to 45) 40% better than placebo in patients already taking statins by hampering the effects of the CETP enzyme. Another potent CETP-inhibitor – torcetrapib – made similar headlines in 2006 when it boosted HDL and reduced LDL like nothing else before it, but those headlines were overshadowed when 60% excess mortality occurred in people taking the drug versus those on placebo. So far, anacetrapib seems safe enough, but I’m not holding my breath. I tend to get a little uneasy when we change a single variable and mess with enzymatic pathways in a very complex closed system, with a single goal (raise that HDL, drop that LDL!) in mind. Focusing on numbers that are largely an indication of your lifestyle without doing anything about the lifestyle itself is like pissing into the wind: quite often, it’ll splash all over you, and you’re lucky if it’s just the shoes.
Next on the musings list, the NY Times Magazine recently published a story by the father of a child with severe epilepsy who’s been keeping it in check with a ketogenic diet. This is great. I mean, this is common knowledge in informed circles, but, as you’ll read in the op-ed, most folks are completely unaware of the efficacy of the keto diet in dealing with epilepsy. The author himself is (or initially was) a bit skeptical of all the fat his kid has to eat. But it works. More than 150 hospitals now offer keto programs to epileptic children, up from just 15 in 1997. The mainstream is successfully implementing a treatment that doesn’t involve prescriptions – and researchers are looking into ketogenic diets for other ailments, including certain cancers (tumors love glucose, after all) and various neurological disorders (Parkinson’s, Alzheimer’s). And now, it’s being discussed (up to more than 250 comments, mostly supportive, though I didn’t read ‘em all and I’m sure I missed a few “lol, Atkins” type responses) and passed around (5th most emailed story) in one of the biggest papers around.
See? There’s hope. They’ll come around.
Wrapping up this round of Monday Musings I’m pleased to announce a couple new Primal Fuel developments. Thanks to the amazing response I’ve been able to broker a special deal with my suppliers. This means cost savings and, as promised, I’m passing these savings on to you. Starting today the regular price of a single canister of Primal Fuel is only $79 + S&H – a $20 savings off the original price.
Primal Fuel on automatic delivery will remain at $79 and you’ll still get free S&H (which runs at over $10 per order), but now you’ll also get a free Primal Fuel Blender Bottle with your first order. Thanks to everyone for the early support and Grok on!